Pharmacotherapy of obesity: Emerging drugs and targets

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 2, 2009, Pages 195-207

  Chakrabarti, Ranjan ^a  

^a IDA   (India)

Author keywords

Appetite regulation; Central targets of obesity; Metabolic syndrome; Peripheral targets of obesity

Indexed keywords

A 71378; ACETYL COENZYME A CARBOXYLASE; AMFEBUTAMONE; ANTIOBESITY AGENT; ARL 15849; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; C 75; CERULENIN; CETILISTAT; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CP 640186; CP 945598; DIACYLGLYCEROL ACYLTRANSFERASE; DRF 2655; FATTY ACID SYNTHASE INHIBITOR; GI 181771; GW 0072; LG 100641; LIRAGLUTIDE; LORCASERIN; MELANIN CONCENTRATING HORMONE ANTAGONIST; MELANOCORTIN 4 RECEPTOR AGONIST; MELANOCORTIN RECEPTOR AGONIST; MIFOBATE; MK 0557; MLN 4760; NALTREXONE; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NGD 4715; PEPTIDE YY [3-36]; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHENTERMINE; PLACEBO; RIMONABANT; SEROTONIN 2C AGONIST; SIBUTRAMINE; TARANABANT; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZONISAMIDE;

ABDOMINAL DISCOMFORT; ANXIETY DISORDER; APPETITE; CLINICAL TRIAL; COGNITIVE DEFECT; DIZZINESS; DRUG MECHANISM; DRUG TARGETING; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HEADACHE; HUMAN; INTESTINE; LOW DRUG DOSE; METABOLIC PARAMETERS; METABOLIC RATE; METABOLIC SYNDROME X; MOOD DISORDER; NAUSEA; NONHUMAN; OBESITY; PARESTHESIA; REVIEW; VOMITING; ANIMAL; CALORIC INTAKE; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENERGY METABOLISM; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ANTI-OBESITY AGENTS; APPETITE; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; ENERGY INTAKE; ENERGY METABOLISM; GASTROINTESTINAL TRACT; HUMANS; METABOLIC SYNDROME X; OBESITY;

EID: 64349117818     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220802637063     Document Type: Review

References (119)

1. Flegal KM, Carrol MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002 ; 288 (14): 1723-1727
2. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003 ; 289 (1): 76-79
3. Kopelman PG. Obesity as a medical problem. Nature 2000 ; 404 (6778): 635-643
4. Cooke D, Bloom S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov 2006 ; 5 (11): 919-931
5. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995 ; 332 (10): 621-628
6. Friedman JM. Modern science versus the stigma of obesity. Nat Med 2004 ; 10 (6): 563 -9 • A comprehensive review on the scientific basis of obesity.
7. Barsh GS, Schwartz MW. Genetic approaches to studying energy balance: perception and integration. Nat Rev Genet 2002 ; 3 (8): 589-600
8. Schultz W. Getting formal with dopamine and reward. Neuron 2002 ; 36 : 241-263
9. Berridge KC. Motivation concepts in behavioral neuroscience. Physiol Behav 2004 ; 81 (2): 179-209
10. Alvaro JD, Tatro JB, Quillan JM, et al. Morphine down-regulates melanocortin-4 receptor expression in brain regions that mediate opiate addiction. Mol Pharmacol 1996 ; 50 (3): 583-591
11. Dryden S, Frankish H, Wang Q, et al. Neuropeptide Y and energy balance: one way ahead for the treatment of obesity? Eur J Clin Invest 1994 ; 24 (5): 293-308
12. Heisler LK, Cowley MA, Tecott LH, et al. Activation of central melanocortin pathways by fenfl uramine. Science 2002 ; 297 (5581): 609-611
13. Lowell BB. Adaptive thermogenesis: turning on the heat. Curr Biol 1998 ; 8 (15): R517 -20
14. Ballinger A. Orlistat in the treatment of obesity. Exp Opin Pharmacother 2000 ; 1 (4): 841-847
15. Astrup A, Hansen DL, Lundsgaard C, et al. Sibutramine and energy balance. Int J Obes Relat Metab Disord 1998 ; 22 (Suppl 1): S30 -5
16. Day C, Baily CJ. Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. Int J Obes Relat Metab Disord 1998 ; 22 : 619-623
17. Ryan DH. The role of silbutramin in the clinical management of obesity. In: Medeiros-Neto G, Halpern A, Bouchard C, editors. Progress in obesity research: 9. John Libby Eurotext, Montrouge, France; 2003 . p. 1051 -1057
18. The endocanabinoid system and its therapeutic exploitation. Nat Rev 2004 ; 3 : 771-784
19. Pertwee RG. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Exp Opin Invest Drugs 2000 ; 9 (7): 1553 -71 •• A comprehensive review of the endocanabinoid system.
20. Pagotto U, Marsicano G, Cota D, et al. The emerging role of endocanabinoid system in endocrine regulation and energy balance. Endocrine Rev 2006 ; 27 : 73-100
21. Ravinet T, C Arnone, M Delgorge, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003 ; 284 (2): R345 -53
22. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the CB1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients. RIO-Europe study. Lancet 2005 ; 365 : 1389-1397
23. Pi-sunyer RK, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a CB1 receptor blocker, on weight and cardiometabolic risk factors in overweight and obese patients. RIO-North America. JAMA 2006 ; 295 : 761-775
24. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfl uramine and other serotonergic medications. Circulation 2000 ; 102 (23): 2836-2841
25. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfl uramine. Mol Pharmacol 2000 ; 57 (1): 75-81
26. Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995 ; 374 (6522): 542-546
27. Nonogaki K, Strack AM, Dallman MF, et al. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med 1998 ; 4 (10): 1152-1156
28. Smith BM, Thompson WJ, Grottick AJ, The potential use of selective 5-HT2c agonists treating obesity. Expert Opin Invest Drugs 2006 ; 15 (3): 257-266
29. Lee MD, Somerville EM, Kennett GA, et al. Tonic regulation of satiety by 5-HT1B receptors in mice: converging evidence from behavioural and c-fos immunoreactivity studies? Eur J Neuroscience 2004 ; 19 (11): 3017-3025
30. Heal DJ, Smith SL, Fisas A, et al. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther 2008 ; 117 (2): 207-231
31. Gantz I, Fong TM. The melanocortin system. Am J Physiol Endocrinol Metab 2003 ; 284 (3): E468 -74 • A comprehensive review on the melanocortin system.
32. Proietto J, Fam BC, Ainslie DA, et al. Novel anti-obesity drugs. Exp Opin Invest Drugs 2000 ; 9 (6): 1317-1326
33. Huszar D, Lynch CA, Fairchild H, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997 ; 88 (1): 131-141
34. Qu D, Ludwig DS, Gammeltoft S, et al. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 1996 ; 380 (6571): 243-247
35. Qu D, Ludwig DS, Gammeltoft S, et al. A role of MCH in the central regulation of feeding behavior. Nature 1996 ; 380 : 243-247
36. Chen Y, Hu C, Hsu CK, et al. Targeted disruption of the melanin-c?ncentrating hormone receptor-1 results in hyperphagia and resistance to diet-induced obesity. Endocrinology 2002 ; 143 (7): 2469-2477
37. Neurogen Press Release; 2008
38. Wieland HA, Bradford SH, Krist B, et al. The role of NPY in metabolic homeostasis: implications for obesity therapy. Exp Opin Invest Drugs 2000 ; 9 (6): 1327-1346
39. Erondu N, Gantz I, Musser B, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006 ; 4 : 274-282
40. Gantz I, Erundo N, Mallick M, et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 2007 ; 92 (5): 1754-1757
41. Gauthier C, Tavernier G, Charpentier F, et al. Functional β3-adrenoceptor in the human heart. J Clin Invest 1996 ; 98 (2): 556-562
42. Chamberlain PD, Jennings KH, Paul F, et al. The tissue distribution of the human β3-adrenoceptor studied using a monoclonal antibody: direct evidence of the β3-adrenoceptor in human adipose tissue, atrium and skeletal muscle. Int J Obes Relat Metab Diord 1999 ; 23 (10): 1057-1065
43. Himms-hagen J. Brown adipose tissue thermogenesis and obesity. Prog Lipid Res 1989 ; 28 : 67-115
44. Weyer C, Gautier JF, Danforth E Jr, et al. Development of beta3-adrenoceptor agonists for the treatment of obesity and diabetes-an update. Diabetes Metab 1999 ; 25 (1): 11-21
45. Coleman RA, Lee DP, Enzymes OF, et al. Prog Lipid Res 2004 ; 43 (2): 134-176
46. Cases S, Smith SJ, Zheng YW, et al. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci USA 1998 ; 95 (22): 13018-13023
47. Cases S, Stone SJ, Zhou P, et al. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem 2001 ; 276 (42): 38870-38876
48. Tomoda H, Namatame I, Omura S. Microbial metabolites with inhibitory activity against lipid metabolism. Proc Jpn Acad Ser B:Phys Biol Sci 2002 ; 78 (8): 217-240
49. Smith S, Witkowski A, Joshi AK. Structural and functional organization of the animal fatty acid synthase. Prog Lipid Res 2003 ; 42 (4): 289-317
50. Jayakumar A, Tai MH, Huang WY, et al. Human fatty acid synthase: properties and molecular cloning. Proc Natl Acad Sci 1995 ; 92 (19): 8695-8699
51. Shi Y, Burn P. Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. Nat Rev Drug Discov 2004 ; 3 (8): 695 -710 • A comprehensive review on lipid metabolizing enzymes.
52. Loftus TM, Jaworsky DE, Frehywot GL, et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 2000;288(5475):2379-2381
53. Shimokawa T, Kumar MV, Lane MD. Differential effects of a centrally acting fatty acid synthase inhibitor in lean and obese mice. Proc Natl Acad Sci 2002 ; 99 (4): 1921-1925
54. Abu-elheiga L, Almarza-ortega DB, Baldini A, et al. Human acetyl-CoA carboxyl?se 2. Molecular cloning, characterization, chromosomal mapping, and evidence for two isoforms. J Biol Chem 1997 ; 272 (16): 10669-10677
55. Abu-elheiga L, Brinkley WR, Zhong L, et al. The subcellular localization of acetyl-CoA carboxylase 2. Proc Natl Acad Sci 2000 ; 97 (4): 1444-1449
56. Abu-elheiga L, Oh W, Kordari P, et al. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high- carbohydrate diets. Proc Natl Acad Sci 2003 ; 100 (18): 10207-10212
57. Pfizer Products, Inc. ACC Inhibitors. WO2003072197; 2003.
58. Chem Abstr 2003 ; 139 : 230625
59. Arbeeny CM, Meyers DS, Bergquist KE, et al. Inhibition of fatty acid synthesis decreases very low density lipoprotein secretion in the hamster. J Lipid Res 1992 ; 33 (6): 843-851
60. Harwood HJ Jr, Petras SF, Shelly LD, et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J Biol Chem 2003 ; 278 (39): 37099-37111
61. Harwood HJ. Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. Exp Opin Ther Targets 2005 ; 9 (2): 267-281
62. Zhang H, Yang Z, Shen Y, et al. Crystal structure of the carboxyltransferase domain of acetyl-coenzyme A carboxylase. Science 2003 ; 299 (5615): 2064-2067
63. Ntambi JM, Miyazaki M. Recent insights into stearoyl-CoA desaturase-1. Curr Opin Lipidol 2003 ; 14 (3): 255-261
64. Dobrzyn P, Dobrzyn A, Miyazaki M, et al. Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver Proc Natl Acad Sci 2004 ; 101 (17): 6409-6414
65. Miyazaki M, Man WC, Ntambi JM. Targeted disruption of stearoyl-CoA desaturase1 gene in mice causes atrophy of sebaceous and meibomian glands and depletion of wax esters in the eyelid. J Nutr 2001 ; 131 (9): 2260-2268
66. Cohen P, Miyazaki M, Socci ND, et al. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 2002 ; 297 (5579): 240-243
67. Miyazaki M, Dobrzyn A, Elias PM, et al. Steroyl-CoA desaturase-2 gene expression is required for lipid synthesis during early skin and liver development. Proc Natl Acad Sc 2005 ; 102 (85): 12501-12506
68. Haas MJ, Cichowicz DJ, Bailey DG. Purification and characterization of an extracellular lipase from fungus Rhizopus delkemar. Lipids 1992 ; 27 : 571-576
69. Fong TM. Advances in anti-obesity therapeutics. Exp Opin Invest Drugs 2005 ; 14 (3): 243-250
70. Rondinone CM. Diabetes: the latest developments in inhibitors, insulin sensitisers, new drug targets and novel approaches. October 18-19, 2004, The Hatton, London, UK. Exp Opin Ther Targets 2005 ; 9 (2): 415 -8 •• An excellent review on antidiabetic and metabolic syndrome therapy.
71. Das SK, Chakrabarti R. Non-insulin dependent diabetes mellitus: present therapies and new drug targets. Mini Rev Med Chem 2005 ; 5 (11): 1019-1034
72. Moran TH, Schwartz GJ, et al. Neurobiology of ?holecystokinin. Crit Rev Neurobiol 1994 ; 9 (1): 1-28
73. Dunlop J. CCK receptor antagonists. Gen Pharmacol 1998 ; 31 (4): 519-524
74. Szewczyk JR, Laudeman C. CCK1R agonists: a promising target for the pharmacological treatment of obesity. Curr Top Med Chem 2003 ; 3 (8): 837-854
75. Holladay MW, Bennett MJ, Tufano MD, et al. Synthesis and biological activity of CCK heptapeptide analogues. Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro, and appetite suppression in vivo. J Med Chem 1992 ; 35 (16): 2919-2928
76. Lin CW, Holladay MW, Witte DG, et al. A71378: a CCK agonist with high potency and selectivity for CCK-A receptors. Am J Physiol 1990 ; 258 (4 Pt 1): G648 -51
77. Pierson ME, Comstock JM, Simmons RD, et al. Synthesis and biological evaluation of potent, selective, hexapeptide CCK-A agonist anorectic agents. J Med Chem 1997 ; 40 (26): 4302-4307
78. Simmons RD, Blosser JC, Rosamond JD. FPL 14294: a novel CCK-8 agonist with potent intranasal anorectic activity in the rat. Pharmacol Biochem Behav 1994 ; 47 (3): 701-708
79. Jordan J, Greenway FL, Leiter LA, et al. Stimulation of cholecystokinin A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther 2007 ; 83 : 281-287
80. Cummings DE, Overduin J, Foster-schubert KE. Roles of ghrelin in the regulation of apetite and body weight. Curr Opin Endocrinol Diabetes 2005 ; 12 : 72-79
81. Kojima M, Hosoda H, Date Y. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999 ; 402 (6762): 656-660
82. Wren AM, Seal LJ, Cohen MA. Ghrelin enhances apetite and increases food intake in humans. J Clin Endocrinol Metab 2001 ; 86 : 5592-5595
83. Beck B, Richy S, Sticker-krangard S. Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats. Life Sci 2004 ; 76 (4): 473-478
84. Cummings DE, Foster-schubert KE, Overduin J. Ghrelin and energy balance: focus on current controversies. Curr Drug Targets 2005 ; 6 (2): 153-169
85. Barton M, Carmona R, Ortmann J, et al. Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. Int J Biochem Cell Biol 2003 ; 35 (6): 826-837
86. Chakrabarti R, Rajagopalan R. The role of PPARs in obesity and other insulin resistance associated disorders. Curr Med Chem Immun Endoc Metab Agents 2004 ; 4 : 67 -72 •• A comprehensive review on role of PPAR on obesity and metabolism.
87. Doggrell S. Do peroxisome proliferation receptor- γ antagonists have clinical potential as combined antiobesity and antidiabetic drugs? Exp Opin Invest Drugs 2003 ; 12 (4): 713-716
88. Oberfield JL, Collins JL, Holmes CP, et al. A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation. Proc Natl Acad Sci 1999 ; 96 (11): 6102-6106
89. Mukherjee R, Hoener PA, Jow L, et al. A selective peroxisome proliferator-activated receptor- γ (PPAR γ ) modulator blocks adipocyte differentiation but stimulates glucose?uptake in 3T3-L1 adipocytes. Mol Endocrinol 2000 ; 14 (9): 1425-1433
90. Chaput E, Saladin R, Silvertre M, et al. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun 2000 ; 271 (2): 445-450
91. Mancini FP, Lanni A, Sabatino L, et al. Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. FEBS Lett 2001 ; 491 (1-2): 154-158
92. Vikramadithyan RK, Hiriyan J, Suresh J, et al. DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities. Obes Res 2003 ; 11 (2): 292-303
93. Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR- α . Nature 2003 ; 425 (6953): 90-93
94. Peters JM, Lee SS, Li W, et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β (δ). Mol Cell Biol 2000 ; 20 (14): 5119-5128
95. Wang YX, Lee CH, Tiep S, et al. Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 2003 ; 113 (2): 159-170
96. Merck Frosst, Canada & Co McGill, et al. Protein tyrosine phosphatase-1b (Ptp-1b) deficient mice and uses thereof WO200006712; 2000.
97. Chem Abstr 2000 ; 132 : 150278
98. Bays H, Dujovne C. Anti-obesity drug development. Exp Opin Invest Drugs 2002 ; 11 (9): 1189-1204
99. Hardie DG, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Ann Rev Biochem 1998 ; 67 : 821-855
100. Kemp BE, Mitchelhill KI, Stapleton D, et al. Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci 1999 ; 24 (1): 22 -5 • A comprehensive review on the pathophysiological role of AMP kinase.
101. Zong H, Ren JM, Young LH, et al. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci 2002 ; 99 (25): 15983-15987
102. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999 ; 277 (1 Pt 1): E1 -10
103. Mu J, Brozinick JT Jr, Valladares O, et al. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell 2002 ; 7 (5): 1085-1094
104. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002 ; 415 (6869): 339-343
105. Tomas E, Tsao TS, Saha AK, et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci 2002 ; 99 (25): 16309-16313
106. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002 ; 8 (11): 1288-1295
107. Bergeron R, Russell RR 3rd,?Young LH, et al. Effect of AMPK activation on muscle glucose metabolism in conscious rats. Am J Physiol 1999;276(5 Pt 1):E938-44
108. Hayashi T, Wojtaszewski JF, Goodyear LJ. Exercise regulation of glucose transport in skeletal muscle. Am J Physiol 1997 ; 273 (6 Pt 1): E1039 -51
109. Merrill GF, Kurth EJ, Hardie DG, et al. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol 1997 ; 273 (6 Pt 1): E1107 -12
110. Salt IP, Connell JM, Gould GW. 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) inhibits insulin-stimulated glucose transport in 3T3-L1 adipocytes. Diabetes 2000 ; 49 (10): 1649-1656
111. Les Laboratories. Rault S, Lancelot JC, et al. Imidazopyridine derivatives, preparation method and pharmaceutical compositions containing same. WO2004043957; 2004.
112. Chem Abst 2004 ; 140 : 375173
113. Kim MS, Park JY, Namkoong C, et al. Anti-obesity effects of α-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med 2004 ; 10 (7): 727-733
114. Chapman I, Parker B, Doran S, et al. Low dose pramlintide reduced food intake and meal duration in healthy, normal weight subjects. Obesity 2007 ; 15 (5): 1179-1186
115. Pramlintide and leptin combination treatment demonstrates 12.7 percent weight loss in 24 wk clinical obesity study. Available from: http://investors.amylin.com/ phoenix.zhtml?c=101911#amp;p=irol-news Article#amp;ID=1078402#amp;highlight= [Last accessed 1 December 2008 ].
116. Arone LJ, Thronton-jones ZD. New targets for obesity pharmacotherapy. Clin Pharmacol Ther 2007 ; 81 : 748-752
117. US National Institutes for Health www.ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/
118. Fujioka K, Greenway F, Cowley MG, et al. The 24 week experience with a combination sustained release product of zonisamide and bupropion: evidence of an encouraging benefit:risk profile. Obesity 2007 ; 15 (9): A85
119. Gadde KM, Yonish GM, Foust MS, et al. A 24 wk randomized controlled trial of VI-0521, a combination weight loss therapy in obese adults. Obesity 2006 ; 14 (Suppl): A17